Clarithromycin
Product Images NDC 63304-821

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clarithromycin (NDC 63304-821). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ranbaxy Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

125 mg 100's Bottle Label (Clarisusp1)

This is a medication called Clarithromycin that comes in the form of an oral suspension. The package contains 100 mL of the medication when reconstituted. It is only available with a prescription. The text also includes identification numbers, such as NDC 63304-821-04. There is some unclear text that cannot be evaluated.*

FDA Label Image

250 mg 100's Bottle Label (Clarisusp2)

This is a label of a medication called Clarithromycin, which is a suspension that is meant to be taken orally. The package contains 100 mL of the medication when reconstituted. The medication is available only with a prescription.*

FDA Label Image

250 mg 60's Bottle Label (Claritab1)

The text is a label for a medication called Clarithromycin, which comes in tablet form and is available only with a prescription. The label also includes a National Drug Code number for the medication.*

FDA Label Image

500 mg 60's Bottle Label (Claritab2)

This is a description of a medication called Clarithromycin. It is in the form of tablets and requires a prescription. The National Drug Code (NDC) for this medication is 63304-726-60. There are 60 tablets per container.*

FDA Label Image

Clinical Signs Of Mac (Clinicalsigns)

The provided text contains data regarding resolution of fever, night sweats, weight gain, and hemoglobin increase through different doses of medicine administered. For resolution of fever and night sweats at 6 weeks, a 500 mg dose resulted in 23% fever resolution and 85% night sweats resolution. Weight gain of over 3% was observed in 33% of patients taking a 500 mg dose, while hemoglobin increased by over 1 gram in 58% of patients at the same dose and duration. Higher doses of 1000 and 2000 mg also produced positive outcomes, with varying percentages for each outcome.*

FDA Label Image

Eradication Rates (Eradicatrates)

H. pylori Eradication Rates study H2BA-3001 evaluating the efficacy of RBC 400mg + Clarithromycin as compared to RBC 400mg + Clarithromycin, 500 mg b.id. analyses revealed eradication rate ranging from 69% to 72% in ITT (n=188) and 71% to 74% in Per-Protocol (n=117/162) population, respectively. Confidence interval rates were also recorded.*

FDA Label Image

Survival (Figure1)

FDA Label Image

Mic Ranges (Qcranges)

This text provides information on the acceptable quality antimicrobial agents' minimum inhibitory concentration (MIC) range. It includes the MIC range for Clarithromycin and Amoxicillin in meg/mL, tested against H. Pylori ATCC 43504.*

FDA Label Image

Structural Formula (Structure)

FDA Label Image

Test Results (Testresults)

This appears to be a report on the results of treatment using Clarithromycin for cases involving T pylor po bacteria. The report shows that the treatment was effective in some cases based on the susceptibility test results, but did not eradicate the bacteria in others. The report also shows outcomes for additional treatments involving various medications.*

FDA Label Image

Susceptibility Tests (Testwithhpylori)

This is a table showing interpretive criteria for susceptibility testing of H. pylori with two antibiotics: Clarithromycin and Amoxicillin. The table indicates the minimum inhibitory concentration (MIC) in mcg/mL for each antibiotic and the corresponding interpretation of susceptibility as either susceptible (S), intermediate (I), or resistant (R).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.